Astrazeneca (AZN) Long-Term Deferred Tax (2009 - 2026)

Astrazeneca's Long-Term Deferred Tax history runs 18 years deep, the most recent figure standing at $6.5 billion for Q2 2026.

• In Q2 2026, Long-Term Deferred Tax rose 3.69% year-over-year to $6.5 billion; the TTM figure through Jun 2026 stood at $6.5 billion (up 3.69% YoY), while the FY2025 annual figure was $5.8 billion, down 19.19% from the prior year.
• Long-Term Deferred Tax for Q2 2026 stood at $6.5 billion, up from $5.6 billion in the prior quarter.
• The five-year high for Long-Term Deferred Tax was $7.2 billion in Q4 2024, with the low at $3.3 billion in Q4 2022.
• The 5-year median for Long-Term Deferred Tax is $4.7 billion (2023), against an average of $5.0 billion.
• The sharpest annual moves came in 2022 and 2024: Long-Term Deferred Tax fell 24.64% in 2022, then soared 52.63% in 2024.
• Astrazeneca's Long-Term Deferred Tax stood at $3.3 billion in 2022, then soared by 44.59% to $4.7 billion in 2023, then jumped by 52.63% to $7.2 billion in 2024, then fell by 19.19% to $5.8 billion in 2025, then gained by 11.48% to $6.5 billion in 2026.
• Business Quant data shows AZN's Long-Term Deferred Tax at $6.5 billion in Q2 2026, $5.6 billion in Q1 2026, and $5.8 billion in Q4 2025.